日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis

一项针对晚期骨髓纤维化的新型泛赖氨酰氧化酶抑制剂 PXS-5505 的 I/IIa 期试验

Vachhani, Pankit; Tan, Peter; Watson, Anne-Marie; Wu, Shang-Ju; Baker, Ross; Cheung, Stanley; Lee, Sung-Eun; Chen, Chih-Cheng; Chen, Tsai-Yun; Hsiao, Hui-Hua; Lee, Jae Hoon; Masarova, Lucia; Tan, Shuh Ying; Baskar, Jana; Charlton, Brett; Findlay, Alison; Hamprecht, Dieter; Jarolimek, Wolfgang; Leadbetter, Joanna; Miller, John; Morgan, Kristen; Zahoor, Amna; Hobbs, Gabriela

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement.

小分子 LOXL2 抑制剂 SNT-5382 可减少心脏纤维化,并实现强大的临床靶点结合

Perryman Lara, Findlay Alison, Baskar Jana, Charlton Brett, Foot Jonathan, Hamilton Ross, Hamprecht Dieter, Joshi Amar, Stolp Jessica, Turner Craig, Zahoor Amna, Zhou Wenbin, López Begoña, Ravassa Susana, González Arantxa, Jarolimek Wolfgang